pyrazines has been researched along with Osteolysis in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (34.78) | 29.6817 |
2010's | 15 (65.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
Bakhous, A; Waheed, S; Zhu, H | 1 |
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
Bokhari, SW; Jones, FM | 1 |
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
Azadeh, N; Fonseca, R; Kelemen, K | 1 |
Khan, S; Li, X; Ling, W; Pennisi, A; Yaccoby, S; Zangari, M | 1 |
Drake, MT; Rajkumar, SV | 1 |
Roodman, GD | 2 |
Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
Aoki, K; Eda, H; Kato, S; Marumo, K; Ohkawa, K; Okawa, Y; Takada, K; Tanaka, T | 1 |
Abildgaard, N; Delaissé, JM; Garnero, P; Lund, T; Ormstrup, T; Pedersen, PT; Plesner, T; Søe, K | 1 |
Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS | 1 |
Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L | 1 |
Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B | 1 |
Cheng, T; Mao, X; Pan, X; Zhang, X | 1 |
Cheng, T; Mao, X; Pan, X; Peng, X; Zhang, X; Zhao, S | 1 |
Brunton, VG; Idris, AI; Logan, JG; Marino, S; Muir, M; Sophocleous, A | 1 |
Mundy, GR; Oyajobi, BO | 1 |
Dimopoulos, MA; Rahemtulla, A; Terpos, E | 1 |
Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Müller, C; Schulz, CO; Sezer, O; Zavrski, I | 1 |
2 review(s) available for pyrazines and Osteolysis
Article | Year |
---|---|
Pathogenesis of myeloma bone disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Denosumab; Fractures, Spontaneous; Glucocorticoids; Humans; Hypercalcemia; Immunologic Factors; Interleukins; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteoclasts; Osteolysis; Pyrazines; RANK Ligand; Stromal Cells; Wnt Proteins | 2009 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine | 2005 |
2 trial(s) available for pyrazines and Osteolysis
Article | Year |
---|---|
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Pyrazines | 2010 |
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteolysis; Protease Inhibitors; Pyrazines | 2006 |
19 other study(ies) available for pyrazines and Osteolysis
Article | Year |
---|---|
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections | 2014 |
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Development; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protease Inhibitors; Pyrazines; Rabbits | 2009 |
Effects of bortezomib on bone disease in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoclasts; Osteolysis; Pyrazines | 2009 |
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines | 2009 |
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Topics: 3T3 Cells; Acyltransferases; Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Fibroblast Growth Factor 2; Humans; Mice; Models, Biological; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; RNA, Messenger; Transcription Factors | 2010 |
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2010 |
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction | 2011 |
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2011 |
Therapeutic potential of the proteasome inhibitor Bortezomib on titanium particle-induced inflammation in a murine model.
Topics: Animals; Boronic Acids; Bortezomib; Female; I-kappa B Kinase; Inflammation; Inflammation Mediators; Joint Prosthesis; Mice; Mice, Inbred BALB C; NF-kappa B; Osteolysis; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; Titanium; Tumor Necrosis Factor-alpha | 2012 |
Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apoptosis; Arthroplasty, Replacement; Boronic Acids; Bortezomib; Female; Inflammation; Mice; Mice, Inbred BALB C; Osteolysis; Osteoprotegerin; Prosthesis Failure; Proteasome Inhibitors; Pyrazines; Random Allocation; RANK Ligand; Titanium; TNF Receptor-Associated Factor 6; Vascular Endothelial Growth Factors | 2012 |
Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Topics: Animals; Bone Remodeling; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Mice; Osteoclasts; Osteolysis; Protein-Tyrosine Kinases; Pyrazines; Receptor, IGF Type 1 | 2013 |
Role of the bone marrow microenvironment in multiple myeloma.
Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |